Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Severe and Asymptomatic Data Could Give Moderna’s COVID-19 Vaccine Slight Edge Over Pfizer’s

Dec 15 2020

• By Sarah Karlin-Smith

Antibodies immunoglobulins attacking coronavirus covid-19 influenza virus cell, 3D immune system medical illustration background. Corona virus 2019-ncov sars cell, igm. Coronavirus sars-cov-2 disease — • Source: Shutterstock

Related Content

COVID-19 Vaccines: Advisory Committee Picks Apart US FDA Guidance On Efficacy Endpoints

Oct 23 2020

NIH Considering Trial of COVID-19 Vaccines and Asymptomatic Transmission

Dec 14 2020

Pfizer Rose To The COVID-19 Challenge And The Stars Aligned

Dec 12 2020

Pfizer's COVID-19 Vaccine Brings Gaps In Efficacy And Safety Data To US FDA Panel

Dec 09 2020

Pandemic Logistics: US FDA Has Not Verified Some Moderna COVID-19 Vaccine Data And Analyses

Dec 16 2020

Related Companies

Moderna, Inc.

Pfizer Inc.

BioNTech SE

Additional Topics

Companies Regulation Research & Development Vaccines Infectious Diseases BioPharmaceutical

More from Business

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window